Boston Scientific Corporation Company Profile (NYSE:BSX)

Boston Scientific Corporation trades on the New York Stock Exchange (NYSE) under the ticker symbol "BSX."

Boston Scientific Corporation (NYSE:BSX) released its quarterly earnings data on Thursday, July, 27th. The company reported $0.32 earnings per share for the quarter, topping analysts' consensus estimates of $0.31 by $0.01. The company had revenue of $2.26 billion for the quarter, compared to analysts' expectations of $2.21 billion. Boston Scientific Corporation had a net margin of 9.04% and a return on equity of 23.62%. The firm's revenue for the quarter was up 6.2% on a year-over-year basis. During the same quarter last year, the company earned $0.27 earnings per share. View Boston Scientific Corporation's Earnings History.

Boston Scientific Corporation is scheduled to release their next quarterly earnings announcement on Wednesday, October, 25th 2017. View Earnings Estimates for Boston Scientific Corporation.

Boston Scientific Corporation issued an update on its FY17 earnings guidance on Thursday, July, 27th. The company provided EPS guidance of $1.23-1.27 for the period, compared to the Thomson Reuters consensus EPS estimate of $1.25. The company issued revenue guidance of $8.89-8.99 billion, compared to the consensus revenue estimate of $8.87 billion.Boston Scientific Corporation also updated its Q3 guidance to $0.29-0.31 EPS.

16 analysts have issued 12 month price targets for Boston Scientific Corporation's shares. Their forecasts range from $28.00 to $32.00. On average, they expect Boston Scientific Corporation's share price to reach $30.19 in the next year. View Analyst Ratings for Boston Scientific Corporation.

Here are some recent quotes from research analysts about Boston Scientific Corporation stock:

• 1. Jefferies Group LLC analysts commented, "We are re-establishing estimates, a Buy rating and $14.00 PT for Flex Pharma. Flex is developing FLX-787, an innovative anti-cramp drug in amyotrophic lateral sclerosis (ALS), Charcot-Marie-Tooth disease (CMT) and multiple sclerosis (MS). We believe CMT , on which we base our PT , has the highest chance of success. We anticipate Ph2 data in 1Q’18 (MS) and 3Q’18 (ALS, CMT). In 2Q’16, Flex launched HOTSHOT , a consumer beverage for exercise- associated muscle cramps that works via the same mechanisms as FLX-787." (9/7/2017)
• 2. According to Zacks Investment Research, "Boston Scientific posted a better-than-expected second quarter, with earnings and revenues both remaining ahead of the Zacks Consensus Estimate. On a positive note, the company is leaving no stone unturned to strengthen its core businesses and invest more in global markets. Among the recent developments, worth mentioning is the company’s acquisition of Symetis, in a bid to fortify its structural heart business in Europe. We are also encouraged with the company gaining a number of product approvals both in the domestic and overseas markets. Notably, the company received an FDA approval for the RESONATE family of ICD and CRT-D systems. Yet, the recent recall of its Lotus range of heart devices hampered sales in the quarter. Also the unimpressive defibrillator performance within the core CRM continues to remain a drag. We are still concerned about the foreign exchange headwind. In general, over the past three months, Boston Scientific is trading below the broader industry." (7/31/2017)
• 3. Needham & Company LLC analysts commented, "BSX beat consensus 1Q17 revenue but missed consensus EPS due to expense associated with the Lotus withdrawal. Management raised its revenue guidance but maintained its EPS guidance for 2017. BSX’s organic revenue growth slowed slightly to 9% in 1Q17 from 10% in 4Q16 despite facing a more difficult comp. MedSurg growth accelerated and offset slower Cardiovascular growth as BSX lapped the US Synergy launch. Margins were below expectations with BSX’s gross margin down 170 bps Y/Y and operating margin down 210 bps Y/Y but this was mostly due to the impact of the Lotus withdrawal." (4/27/2017)

Some companies that are related to Boston Scientific Corporation include Thermo Fisher Scientific (TMO), Danaher Corporation (DHR), Koninklijke Philips N.V. (PHG), Intuitive Surgical (ISRG), Illumina (ILMN), Edwards Lifesciences Corporation (EW), Cerner Corporation (CERN), Agilent Technologies (A), Waters Corporation (WAT), ResMed (RMD), Hologic (HOLX), Varian Medical Systems (VAR), PerkinElmer (PKI), ABIOMED (ABMD), Bruker Corporation (BRKR), Alere (ALR), Quidel Corporation (QDEL) and Accelerate Diagnostics (AXDX).

Boston Scientific Corporation's management team includes the folowing people:

• Michael F. Mahoney, Chairman of the Board, President, Chief Executive Officer
• Daniel J. Brennan, Chief Financial Officer, Executive Vice President
• Timothy A. Pratt, Chief Administrative Officer, Executive Vice President, General Counsel, Secretary
• Supratim Bose, Executive Vice President; President, Asia-Pacific, Middle East and Africa
• Keith D. Dawkins M.D., Global Chief Medical Officer, Executive Vice President
• Joseph M. Fitzgerald, Executive Vice President; President - Rhythm Management
• Edward F. Mackey, Executive Vice President - Operations
• Ian T. Meredith AM, Executive Vice President, Global Chief Medical Officer
• Michael P. Phalen, Executive Vice President; President - MedSurg
• Wendy Carruthers, Senior Vice President - Human Resources

Boston Scientific Corporation's stock is owned by a number of of retail and institutional investors. Top institutional investors include FMR LLC (12.72%), Capital World Investors (7.43%), BlackRock Inc. (7.31%), Vanguard Group Inc. (6.83%), State Street Corp (4.17%) and Janus Henderson Group PLC (2.83%). Company insiders that own Boston Scientific Corporation stock include Charles J Dockendorff, Daniel J Brennan, David A Pierce, Ernest Mario, Jeffrey B Mirviss, John Bradley Sorenson, Joseph Michael Fitzgerald, Karen Prange, Keith D Dawkins, Kevin J Ballinger, Maulik Nanavaty, Michael F Mahoney, Michael P Phalen, Timothy A Pratt and Wendy Carruthers. View Institutional Ownership Trends for Boston Scientific Corporation.

Boston Scientific Corporation's stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, Artisan Partners Limited Partnership, Standard Life Investments LTD, Marshall Wace North America L.P., Arrowstreet Capital Limited Partnership, Gotham Asset Management LLC, Bollard Group LLC and BNP Paribas Arbitrage SA. Company insiders that have sold Boston Scientific Corporation stock in the last year include Daniel J Brennan, David A Pierce, John Bradley Sorenson, Keith D Dawkins, Kevin J Ballinger, Maulik Nanavaty, Michael P Phalen, Timothy A Pratt and Wendy Carruthers. View Insider Buying and Selling for Boston Scientific Corporation.

Boston Scientific Corporation's stock was bought by a variety of institutional investors in the last quarter, including Janus Henderson Group PLC, Jennison Associates LLC, BlackRock Inc., Los Angeles Capital Management & Equity Research Inc., Vanguard Group Inc., Winslow Capital Management LLC, Capital World Investors and Lord Abbett & CO. LLC. View Insider Buying and Selling for Boston Scientific Corporation.

Shares of Boston Scientific Corporation can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of Boston Scientific Corporation stock can currently be purchased for approximately $28.76.